00:12 , Jul 20, 2019 |  BioCentury  |  Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Rat studies suggest promoting the expression of TRESK or inhibiting its negative regulators VEGF and VEGFR2 could help treat pain associated with bone metastasis. In a rat model of bone metastasis-associated pain, TRESK...
20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
01:22 , Jan 4, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
22:05 , Jul 25, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; high throughput screening; toxicology A high throughput yeast- and DNA barcode-based platform could be used to screen for changes in protein-protein interactions induced by drug compounds. The platform involves first generating libraries...
19:11 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Aurinia starts Phase III AURORA trial of voclosporin for lupus nephritis

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) began the Phase III AURORA trial evaluating Luveniq voclosporin (LX211) to treat lupus nephritis. The double-blind, international trial will enroll about 320 patients to receive twice-daily 23.7 mg voclosporin plus...
15:46 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Voclosporin regulatory update

Aurinia said it believes results from the planned Phase III AURORA trial and the completed Phase IIb AURA-LV trial of voclosporin will be sufficient for regulatory submissions of the product in the EU and Japan...
23:42 , Apr 7, 2017 |  BC Extra  |  Company News

Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed Phase IIb study of voclosporin ( LX211 ) will be sufficient for regulatory submissions in the EU...
00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells...